Current Report Filing (8-k)
29 4월 2023 - 6:08AM
Edgar (US Regulatory)
0001571934
false
0001571934
2023-04-24
2023-04-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 24, 2023
Synaptogenix, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
001-40458 |
46-1585656 |
(State or other jurisdiction
of incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
1185
Avenue of the Americas, 3rd
Floor
New York, New
York 10036
(Address of principal executive offices and zip code)
Registrant’s telephone number, including
area code: (973) 242-0005
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which
registered |
Common Stock, $0.0001 par value per share |
|
SNPX |
|
The Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company. x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 3.01 | Notice of Delisting of Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
(a)
On April 24, 2023, Synaptogenix,
Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying the Company that for the preceding 30 consecutive business days, the Company’s common stock did not maintain a minimum
closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).
The notice has no immediate effect on the listing or trading of the Company’s common stock, and the common stock will continue to
trade on The Nasdaq Capital Market under the symbol “SNPX” at this time.
In accordance with Nasdaq Listing
Rule 5810(c)(3)(A), the Company has a grace period of 180 calendar days, or until October 23, 2023, to regain compliance with Nasdaq Listing
Rule 5550(a)(2). Compliance can be achieved automatically and without further action if the closing bid price of the Company’s stock
is at or above $1.00 for a minimum of 10 consecutive business days at any time during the 180-day compliance period, in which case Nasdaq
will notify the Company of its compliance and the matter will be closed.
If, however, the Company does
not achieve compliance with the Minimum Bid Price Requirement by October 23, 2023, the Company may be eligible for additional time to
comply. In order to be eligible for such additional time, the Company will be required to meet the continued listing requirement for market
value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum
Bid Price Requirement, and must notify Nasdaq in writing of its intention to cure the deficiency during the second compliance period,
by effecting a reverse stock split, if necessary.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
By: |
/s/ Robert Weinstein |
|
Name: |
Robert Weinstein |
|
Title: |
Chief Financial Officer |
Date: April 28, 2023
Synaptogenix (NASDAQ:SNPX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Synaptogenix (NASDAQ:SNPX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024